Predictive value of transforming growth factor-β1 in Chagas disease: towards a biomarker surrogate of clinical outcome

dc.creatorSaraiva, Roberto M.
dc.creatorWaghabi, Mariana C.
dc.creatorVilela, Maíra F.
dc.creatorMadeira, Fabiana S.
dc.creatorSilva, Gilberto M. Sperandio da
dc.creatorXavier, Sérgio S.
dc.creatorFeige, Jean J.
dc.creatorHasslocher-Moreno, Alejandro Marcel
dc.creatorAraujo-Jorge, Tania C.
dc.date2016-01-28T12:41:35Z
dc.date2016-01-28T12:41:35Z
dc.date2013
dc.date.accessioned2023-09-26T22:00:54Z
dc.date.available2023-09-26T22:00:54Z
dc.identifierSARAIVA, Roberto M. et al. Predictive value of transforming growth factor-β1 in Chagas disease: towards a biomarker surrogate of clinical outcome. Royal Society of Tropical Medicine and Hygiene Transactions, v. 107, p. 518-525, 2013.
dc.identifier0035-9203
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/12641
dc.identifier10.1093/trstmh/trt050
dc.identifier1878-3503
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8874370
dc.descriptionBackground: Transforming growth factor-b1 (TGF-β1) may be implicated in the development of Chagas heart disease. However, the clinical value of TGF-β1 measurement is yet to be determined. Methods: We retrospectively analyzed the outcome of 54 Chagas disease patients without heart failure and with left ventricular (LV) ejection fraction .45% whose TGF-β1 serum values were determined between January 1998 and December 1999. Primary end point was all-cause mortality and secondary end point was the combination of all-cause mortality or hospitalization due to worsening heart failure or cardiac arrhythmias. Results: TGF-β1 was independently associated with the occurrence of the primary and secondary end points. The optimal cutoff for TGF-β1 to identify the primary end point was 12.9 ng/ml (area under the curve = 0.82, p = 0.004, sensitivity 100%, and specificity 57%) and to identify the secondary end point was 30.8 ng/ml (area under the curve = 0.72, p = 0.03, sensitivity 60%, and specificity 86%). LV ejection fraction and LV end-diastolic diameter were also independent predictors of the primary and secondary endpoints, respectively. Conclusion: The described association between TGF-β1 and clinical outcome provides evidence towards the clinical value of TGF-β1 in Chagas disease.
dc.formatapplication/pdf
dc.languageeng
dc.publisherOxford University Press
dc.rightsrestricted access
dc.subjectChagas disease
dc.subjectHeart failure
dc.subjectTransforming growth factor-b1
dc.subjectEchocardiography
dc.subjectPrognosis
dc.subjectDoença de Chagas
dc.subjectInsuficiência Cardíaca
dc.subjectEcocardiografia
dc.subjectPrognóstico
dc.titlePredictive value of transforming growth factor-β1 in Chagas disease: towards a biomarker surrogate of clinical outcome
dc.typeArticle


Este ítem pertenece a la siguiente institución